-
Je něco špatně v tomto záznamu ?
Modulation of the QT interval duration in hypertension with antihypertensive treatment
J. Klimas, P. Kruzliak, SW. Rabkin,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
ProQuest Central
od 2015-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2009-01-01 do 2015-11-30
Health & Medicine (ProQuest)
od 2015-01-01 do Před 1 rokem
PubMed
25787045
DOI
10.1038/hr.2015.30
Knihovny.cz E-zdroje
- MeSH
- antihypertenziva terapeutické užití MeSH
- elektrokardiografie účinky léků MeSH
- hypertenze diagnóza farmakoterapie patofyziologie MeSH
- hypertrofie levé komory srdeční farmakoterapie patofyziologie MeSH
- lidé MeSH
- srdeční frekvence účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The duration of the QT interval as measured by 12-lead electrocardiography is a measure of myocardial repolarization and is widely used to describe cardiac abnormalities, to determine the presence of cardiac toxicity and to evaluate drug safety. In hypertension, the QT interval is a predictor of the risk of both coronary events and cardiovascular death, after adjusting for the effects of additional risk factors. The mechanism of QT interval prolongation is multifactorial and includes cardiomyocyte hypertrophy and increased left ventricular mass, with accompanying changes in left ventricular transmural dispersion of repolarization, as well as changes in the tone of the autonomic nervous system of some patients with hypertension and mechano-electrical feedback, although this mechanism is less likely. Antihypertensive drugs vary in their effect on QT interval duration. The mechanisms underlying their effect depend on changes in left ventricular mass and autonomic nervous system tone, as well as changes in the activity of cardiac ion channels. Although blood pressure reduction is the primary goal of antihypertensive drug therapy and although the choice of antihypertensive drug treatment regimens varies among different individuals, the data regarding the disparate effects of antihypertensive drugs on the duration of the QT interval warrant consideration when implementing long-term pharmacotherapy for hypertension.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010437
- 003
- CZ-PrNML
- 005
- 20160414103242.0
- 007
- ta
- 008
- 160408s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/hr.2015.30 $2 doi
- 024 7_
- $a 10.1038/hr.2015.30 $2 doi
- 035 __
- $a (PubMed)25787045
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Klimas, Jan $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic.
- 245 10
- $a Modulation of the QT interval duration in hypertension with antihypertensive treatment / $c J. Klimas, P. Kruzliak, SW. Rabkin,
- 520 9_
- $a The duration of the QT interval as measured by 12-lead electrocardiography is a measure of myocardial repolarization and is widely used to describe cardiac abnormalities, to determine the presence of cardiac toxicity and to evaluate drug safety. In hypertension, the QT interval is a predictor of the risk of both coronary events and cardiovascular death, after adjusting for the effects of additional risk factors. The mechanism of QT interval prolongation is multifactorial and includes cardiomyocyte hypertrophy and increased left ventricular mass, with accompanying changes in left ventricular transmural dispersion of repolarization, as well as changes in the tone of the autonomic nervous system of some patients with hypertension and mechano-electrical feedback, although this mechanism is less likely. Antihypertensive drugs vary in their effect on QT interval duration. The mechanisms underlying their effect depend on changes in left ventricular mass and autonomic nervous system tone, as well as changes in the activity of cardiac ion channels. Although blood pressure reduction is the primary goal of antihypertensive drug therapy and although the choice of antihypertensive drug treatment regimens varies among different individuals, the data regarding the disparate effects of antihypertensive drugs on the duration of the QT interval warrant consideration when implementing long-term pharmacotherapy for hypertension.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antihypertenziva $x terapeutické užití $7 D000959
- 650 _2
- $a elektrokardiografie $x účinky léků $7 D004562
- 650 _2
- $a srdeční frekvence $x účinky léků $7 D006339
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypertenze $x diagnóza $x farmakoterapie $x patofyziologie $7 D006973
- 650 _2
- $a hypertrofie levé komory srdeční $x farmakoterapie $x patofyziologie $7 D017379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Centre, St Anne's University Hospital and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Rabkin, Simon W $u Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- 773 0_
- $w MED00006041 $t Hypertension research official journal of the Japanese Society of Hypertension $x 1348-4214 $g Roč. 38, č. 7 (2015), s. 447-54
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25787045 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160414103326 $b ABA008
- 999 __
- $a ok $b bmc $g 1113866 $s 934805
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 38 $c 7 $d 447-54 $e 20150319 $i 1348-4214 $m Hypertension research $n Hypertens Res $x MED00006041
- LZP __
- $a Pubmed-20160408